Neurocrine reports progress for CAH drug as Voyager partnership shifts

Neurocrine Biosciences (Nasdaq: NBIX), the American biotech, has unveiled new data showing its drug Crenessity (crinecerfont) may help children and adults with classic congenital adrenal hyperplasia (CAH) achieve better hormone balance and reduce steroid use. The findings were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando.

In the Phase III studies, 90% of pediatric patients taking Crenessity hit at least one target for lowering androgen or steroid levels, compared to just 21% on placebo.

For adults, the drug also improved certain reproductive hormone levels, even as patients were able to cut back on steroid doses. In both age groups, the most common side effects included headache and fatigue, with adrenal crises rare.